MacroGenics, Inc. (MGNX)

MacroGenics' stock price has declined by 43.71% in the past six months, but recently crossed above its 50-day moving average in January 2026. In Q3 2025, MacroGenics reported EPS of $0.27, beating estimates of ($0.48), and revenue of $72.84 million, also surpassing expectations. The company participated in the Stifel 2025 Healthcare Conference in November 2025 and is scheduled to participate in the 8th Annual Evercore Healthcare Conference in November 2025. MacroGenics, Inc. was dropped from the Russell 3000E Index and the Russell 2000 Value Index in June 2025. Executive and board changes were announced in August 2025, and Scott Koenig will step down as CEO early in 2026. As of January 2026, analysts have a consensus "Hold" rating for MGNX, with an average target price of $3.60.

There is no information available to indicate demand seasonality for MacroGenics, Inc.'s products and services. Demand is typically driven by medical need, clinical trial outcomes, and regulatory approvals rather than seasonal patterns.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based therapeutics. The company operates in the Healthcare sector, specifically in Biotechnology: Pharmaceutical Preparations. Headquartered in Rockville, Maryland, MacroGenics modulates the human immune response for treating cancer, autoimmune disorders, and infectious diseases. Its pipeline includes MARGENZA® (margetuximab) for metastatic HER2-positive breast cancer, Lorigerlimab for metastatic castration-resistant prostate cancer, platinum-resistant ovarian cancer, and clear cell gynecologic cancer, MGC026 and MGC028 Antibody-Drug Conjugates (ADCs), and other product candidates like flotetuzumab, retifanlimab, enoblituzumab, tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.

MacroGenics, Inc. is based in Rockville, Maryland, United States. The company focuses on discovering, developing, manufacturing, and commercializing antibody-based therapeutics to treat cancer in the United States, indicating its primary market and operational focus.

MacroGenics is recognized as a pioneer in antibody-based therapeutics, known for its DART® and TRIDENT® technology platforms. The company emphasizes pioneering novel modalities and supporting innovation through disciplined financial management and strategic partnerships, with a core value of "Patients First" driving pipeline decisions. While financial losses and revenue shortfalls could affect perception, no specific events have explicitly damaged its brand reputation in the past year.

MacroGenics, Inc. has substantial institutional ownership, with 186 institutional owners and shareholders holding a total of 47,788,320 shares, representing over 50% of the company. Major institutional owners include Bellevue Group AG, Armistice Capital, Llc, Vanguard Group Inc, Frazier Life Sciences Management, L.P., Acadian Asset Management Llc, Millennium Management Llc, Wasatch Advisors Inc (or Wasatch Global Investors Inc), Renaissance Technologies Llc, and BlackRock, Inc. Individual insiders own approximately US$3.0 million worth of shares. The general public holds about a 21% stake, and hedge funds control about 9.4% of the shares.